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The aim of this study was to test the hypothesis that C-reactive protein (CRP) protects
against the development of atherosclerosis and that a conformational alteration of
wild-type CRP is necessary for CRP to do so. Atherosclerosis is an inflammatory
cardiovascular disease and CRP is a plasma protein produced by the liver in
inflammatory states. The co-localization of CRP and low-density lipoproteins (LDL) at
atherosclerotic lesions suggests a possible role of CRP in atherosclerosis. CRP binds
to phosphocholine-containing molecules but does not interact with LDL unless the
phosphocholine groups in LDL are exposed. However, CRP can bind to LDL, without
the exposure of phosphocholine groups, if the native conformation of CRP is altered.
Previously, we reported a CRP mutant, F66A/T76Y/E81A, generated by site-directed
mutagenesis, that did not bind to phosphocholine. Unexpectedly, this mutant CRP,
without any more conformational alteration, was found to bind to atherogenic LDL. We
hypothesized that this CRP mutant, unlike wild-type CRP, could be anti-atherosclerotic
and, accordingly, the effects of mutant CRP on atherosclerosis in atherosclerosis-prone
LDL receptor-deficient mice were evaluated. Administration of mutant CRP into mice
every other day for a few weeks slowed the progression of atherosclerosis. The size
of atherosclerotic lesions in the aorta of mice treated with mutant CRP for 9 weeks
was ∼40% smaller than the lesions in the aorta of untreated mice. Thus, mutant CRP
conferred protection against atherosclerosis, providing a proof of concept that a local
inflammation-induced structural change in wild-type CRP is a prerequisite for CRP to
control the development of atherosclerosis.
Keywords: atherosclerosis, C-reactive protein, inflammation, low-density lipoprotein, phosphocholine

INTRODUCTION
Atherosclerosis is a chronic inflammatory disease whose development begins with the dysfunction
of the endothelium of the arteries. Endothelial dysfunction leads to infiltration of plasma lowdensity lipoprotein (LDL) and monocytes in the arterial wall. LDL is subsequently deposited,
modified and engulfed by monocyte-derived macrophages. Lipid-laden macrophage foam cells are
proinflammatory which enhances the process of the formation of atherosclerotic lesions (1, 2).
The inflammatory microenvironment of atherosclerotic lesions is characterized by macrophage
activation, hypoxia, and lactate and proton generation, resulting in an acidic extracellular pH (3–7).
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of atherosclerosis. Accordingly, in this study, we evaluated the
effects of mutant CRP (F66A/T76Y/E81A) on the development
of atherosclerosis employing LDL receptor-deficient (Ldlr−/− )
mice, an animal model commonly used to investigate molecules
involved in human atherosclerosis.

C-reactive protein (CRP) is a plasma protein produced by
the liver in inflammatory states (8). CRP is also present, colocalized with modified LDL and macrophages, at atherosclerotic
lesions in both humans and experimental animals (9, 10). CRP
is composed of five identical subunits arranged in a pentameric
symmetry. The molecular weight of each subunit is ∼23 kDa and
there are 206 amino acid residues in each subunit. CRP binds to
molecules with exposed phosphocholine (PCh) groups in a Ca2+ dependent manner. There are five PCh-binding sites in the CRP
pentamer, one site per subunit (11, 12).
Oxidized LDL (ox-LDL), enzymatically-modified LDL (ELDL) and acetylated LDL (ac-LDL) are different forms of
modified atherogenic LDL that are used in in vitro experiments
(1, 2, 13). In the presence of Ca2+ , native or recombinant wildtype (WT) CRP interacts with E-LDL due to the exposure of
PCh groups on E-LDL, but does not interact with ox-LDL and
ac-LDL (14–16). In the absence of Ca2+ , WT CRP does not
interact with any form of atherogenic LDL (16–19). The native
pentameric structure of CRP is altered in response to a variety
of experimental conditions (16–23). It has been shown that the
pentameric structure of WT CRP is subtly altered by acidic pH
and by oxidation, and conformationally altered CRP is capable
of binding to atherogenic LDL independent of the PCh-binding
site (17–19). Employing E-LDL, it has also been shown that if
CRP is bound to atherogenic LDL, it prevents the formation of
lipid-laden macrophage foam cells (24). Due to the presence of
CRP at atherosclerotic lesions and due to the binding capability
of CRP for atherogenic LDL under certain conditions, CRP has
been implicated in the development of atherosclerosis (25).
We have previously reported a CRP mutant,
F66A/T76Y/E81A, in which Phe66 , Thr76 , and Glu81 (three
critical amino acid residues in the PCh-binding site) were
substituted with Ala, Tyr, and Ala, respectively, to abolish the
PCh-binding activity of CRP (26). Mutant CRP did not bind to
PCh and was used as a tool to investigate the importance of the
PCh-binding site in CRP-mediated protection of mice against
pneumococcal infection (26). Biochemical characterization of
this mutant CRP, in comparison to that of WT CRP, has been
published previously (26). The overall structure of mutant CRP
was pentameric and the mutation did not affect the stability of
the protein in vivo. Mutant CRP circulated freely in the mouse
serum and its rate of clearance in vivo was similar to that of WT
CRP (26).
Further analysis of F66A/T76Y/E81A mutant CRP, presented
here, revealed that mutant CRP had inadvertently gained the
ability to bind to any protein that was immobilized on microtiter
plates, including atherogenic forms of LDL, without the need
for any further inflammatory milieu-dependent or acidic pHinduced structural change. We, therefore, hypothesized that
mutant CRP might show an atheroprotective effect in murine
models of atherosclerosis. We reasoned that even if there was
no acidic pH around injected mutant CRP in the available
murine models, mutant CRP would be able to recognize and bind
atherogenic LDL and exert a protective effect on the development

MATERIALS AND METHODS
Preparation of F66A/T76Y/E81A Mutant
CRP
The construction of F66A/T76Y/E81A mutant CRP cDNA used
in this study has been reported previously (26). Mutant CRP
was expressed in CHO cells using the ExpiCHO Expression
System (Thermo Fisher Scientific), according to manufacturer’s
instructions. As described previously (26), mutant CRP was
purified from cell culture supernatant by Ca2+ -dependent
affinity chromatography on a phosphoethanolamine-Sepharose
column, since this CRP mutant does not bind to PCh. Mutant
CRP was further purified by gel filtration on a Superose12
column. Eluted mutant CRP was immediately dialyzed against
10 mM Tris-HCl, 150 mM NaCl, pH 7.2 (TBS), containing
2 mM CaCl2 , stored at 4◦ C, and was used within a week.
The purity of CRP was confirmed by using denaturing SDSPAGE. For in vivo experiments, purified mutant CRP was treated
with the Detoxi-Gel Endotoxin Removing Gel (Thermo Fisher
Scientific) according to manufacturer’s instructions. The removal
of endotoxin from mutant CRP preparations was confirmed
by using the Limulus Amebocyte Lysate kit QCL-1000 (Lonza)
according to manufacturer’s instructions.

Solid Phase Ligand-Binding Assay
The solid phase ligand-binding assay was used to determine the
binding of mutant CRP to immobilized proteins, as described
earlier (17–19). Ox-LDL, E-LDL, ac-LDL, factor H (Complement
Technology) and amyloid β peptide 1-42 (Bachem, H-1368)
were used as protein ligands. Ox-LDL, E-LDL, and ac-LDL were
prepared as described previously (17–19, 24). Briefly, microtiter
wells were coated with protein ligands (10 µg/ml) diluted in
TBS and incubated overnight at 4◦ C. The unreacted sites in the
wells were blocked with TBS containing 0.5% gelatin. Freshly
purified mutant CRP was diluted in TBS-Ca (TBS containing
2 mM CaCl2 , 0.1% gelatin and 0.02% Tween 20), added to the
wells, and incubated overnight at 4◦ C. Bound mutant CRP was
detected by using a polyclonal rabbit anti-human CRP antibody
(Millipore Sigma, 235752). HRP-conjugated donkey anti-rabbit
IgG (GE Healthcare) was used as the secondary antibody. Color
was developed using ABTS as the substrate and the OD405 was
read in a plate reader.

Atherosclerosis Protection Experiments
Eight-week-old C57BL/6 male ldlr−/− mice (Jackson Lab,
002207) were used in experiments according to protocols
approved by and conducted in accordance with the guidelines
administered by the Institutional Animal Care and Usage
Committee of East Tennessee State University. Sixty mice were
fed on a high-fat western-type diet (21% fat, 0.2% cholesterol),
purchased from Envigo (TD.88137), for 10 weeks. After 1 week

Abbreviations: CRP, C-reactive protein; LDL, Low-density lipoprotein; Ldlr−/− ,
LDL receptor-deficient; PCh, Phosphocholine; WT, wild-type.
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for mutant CRP-treated group; 12 mice per time point) were
processed, stained and photographed. A representative Sudan
IV-stained aorta is shown in Figure 1B.
To measure the size of atherosclerotic lesions in the aortic
root, 8 µm cross-sections of frozen OCT-embedded heart were
collected from the appearance of the aortic valve leaflets to
their disappearance (48–72 sections per heart). Every other
cross-section of the entire aortic root was stained with Oil
Red O for lipids, counterstained with hematoxylin, and digitally
photographed, as described previously (27). A total of 120
hearts (60 mice for untreated group and 60 mice for mutant
CRP-treated group; 12 mice per time point) were processed. A
representative Oil Red O-stained aortic root section is shown in
Figure 1C.
Digital photographs were acquired with an Olympus BX41
microscope equipped with a CCD color camera (QImaging).
The stained lesion areas were quantified in digital images using
the ImageJ software (28). Quantification of the lesion areas in
the photographs was performed by two observers blinded to
the experimental protocol. Non-parametric test (Mann-Whitney
test) using GraphPad Prism software was employed to calculate
the p-values.

Immunostaining of CRP
Sudan IV-stained aorta was first processed to remove the stain, as
described earlier (29). Immunostaining of CRP was performed
using Vectastain ABC Elite kit (Vector laboratories, PK-6100)
according to manufacturer’s instructions. CRP was detected by
using a polyclonal rabbit anti-human CRP antibody (Millipore
Sigma, 235752). Biotinylated goat-anti rabbit IgG was used
as the secondary antibody. Color was developed using DAB
(Vector laboratories, ImmPACT DAB, SK-4105) as the substrate,
according to manufacturer’s instructions.

FIGURE 1 | Assessment of atherosclerotic lesions in ldlr−/− mice. (A) Protocol
for administration of mutant CRP and for sacrifice of mice after mutant CRP
administration. (B) Quantitation of atherosclerotic lesions in the aorta (en face).
A representative Sudan IV-stained aorta is shown. The red colored areas are
the lesions. Scale bar, 5 mm. (C) Quantitation of atherosclerotic lesions in the
aortic root. A representative Oil Red O-stained aortic root section is shown.
The red colored areas are the lesions. Scale bar, 100 µm.

on high-fat diet, mice were divided into two groups of 30
mice in each group: untreated group and mutant CRP-treated
group. Mice were injected with either TBS (untreated group) or
mutant CRP (50 µg/injection) on alternate days for 9 weeks, via
alternating intravenous and intraperitoneal routes (Figure 1A).
Blood, heart and aorta were collected at five different time points
(weeks 1, 3, 5, 7, and 9), as described previously (27). Briefly,
six mice from each group, at each time point, were sacrificed,
blood was collected by cardiac puncture, and the plasma was
separated and stored frozen. After collecting blood, the heart was
perfused with 10% formalin, followed by removing fat from the
entire aorta. Heart was excised from the aorta, was cut into two
halves, and the upper half with the aortic root was mounted using
OCT medium and stored at −80◦ C. Following heart excision,
aorta was excised and stored in 10% formalin at 4◦ C. The whole
experiment was repeated once more employing another 60 mice
and a separate, freshly purified batch of mutant CRP.

Measurement of Lipoproteins in the
Plasma
The concentrations of high-density lipoprotein (HDL) and LDL
in the plasma were measured using Cholesterol Assay Kit-HDL
and LDL/VLDL (Abcam; ab65390) according to manufacturer’s
instructions. Lipoprotein levels were measured in the pooled
plasma samples collected at weeks 1, 3, 5, 7, and 9 (12 mice per
time point). Unpaired student t-test was employed to calculate
the p-values.

RESULTS
All experiments were performed three times, unless otherwise
mentioned, and comparable results were obtained each time.
Results of a representative experiment are shown in the figures
where the raw data (OD405 ) were used to plot the curves.

Measurement of the Size of
Atherosclerotic Lesions

Mutant CRP Binds to Atherogenic LDL
As shown in Figure 2, mutant CRP bound to all three forms of
atherogenic LDL immobilized on microtiter wells. The binding
occurred at physiological conditions, that is, in the absence of
any protein structure-modifying agent, such as acidic pH. Since
mutant CRP does not bind to PCh (26), the binding of mutant

To measure the size of atherosclerotic lesions in the whole aorta
(en face), aorta was cut open longitudinally, stained with Sudan
IV, and digitally photographed, as described previously (27). A
total of 120 aortae (60 mice for untreated group and 60 mice
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FIGURE 2 | Binding of F66A/T76Y/E81A mutant CRP to immobilized proteins including atherogenic LDL at physiological pH. Microtiter wells were coated with protein
ligands as shown. After blocking the unreacted sites in the wells, mutant CRP diluted in TBS-Ca was added to the wells and incubated for 2 h at 37◦ C. Bound mutant
CRP was detected by using a rabbit anti-human CRP antibody and HRP-conjugated donkey anti-rabbit IgG. Color was developed and the OD was read at 405 nm. A
representative of three experiments are shown.

CRP to either ox-LDL, E-LDL, or ac-LDL was independent of the
PCh groups present in atherogenic LDL. In addition to testing the
binding of mutant CRP to atherogenic LDL, we also included two
other proteins, factor H and amyloid β peptide, in the binding
assay. Mutant CRP also bound to factor H and amyloid β peptide
in a concentration-dependent manner, similar to its binding to
atherogenic LDL. These results suggest that mutant CRP did not
recognize immobilized atherogenic LDL per se, but it recognized
a pattern, as yet undefined, on immobilized proteins in general.

Mutant CRP Reduces Atherosclerotic
Lesions in the Whole Aorta
The total size of all lesion areas in the whole aorta (en face) was
measured. Figure 3 shows the combined results of two separate
experiments with 12 mice in each group, for each time point.
There was no effect of mutant CRP on the en face lesions for the
first 5 weeks. The effect of mutant CRP on the lesion size was
visible once the disease had progressed further. In comparison
to untreated mice, the lesion area in mutant CRP-treated mice
was 30.9% less after 7 weeks and 42% less after 9 weeks of
CRP administration. As shown, in mutant CRP-treated mice,
the lesion area did not increase after 5 weeks unlike in the
untreated group where the lesion area kept increasing for another
2 weeks. Similar results were seen when the data from each
of the two experiments (6 mice/group/time point/experiment)
were analyzed separately (Supplemental Figure 1). We did not
determine the specific stages of atherosclerosis at any time point.

FIGURE 3 | Reduction in the size of atherosclerotic lesions in the aorta of
mutant CRP-treated mice. The scatter plot shows the total atherosclerotic
lesion area in en face aorta from untreated and mutant CRP-treated mice.
Data were collected at five different time points: 1, 3, 5, 7, and 9 weeks after
mutant CRP administration (12 mice per group per time point). Each blue dot
represents one mouse from the untreated group and each green dot
represents one mouse from the mutant CRP-treated group. Horizontal black
lines indicate the median total lesion area for each group. Asterisks denote
statistically significant difference between untreated and mutant CRP-treated
groups (*p ≤ 0.01).

point between untreated and mutant CRP-treated groups of
mice. Similar results were seen when the data from each of
the two experiments (6 mice/group/time point/experiment) were
analyzed separately (Supplemental Figure 2).

The Effects of Mutant CRP Are Not Visible
at the Aortic Root Lesions

Administered Mutant CRP Is Present in the
Aorta

The total size of all lesion areas in the aortic root was measured.
Figure 4 shows the combined results of two separate experiments
using 12 mice in each group, for each time point. As shown,
the disease progressed for the entire duration of 9 weeks in
untreated mice. However, the administration of mutant CRP
did not affect the lesion size at any time point. There was no
statistically significant difference in the lesion size at any time

Frontiers in Immunology | www.frontiersin.org

Immunostaining of CRP in the aorta isolated from mice treated
with mutant CRP for seven weeks was performed to confirm
the presence of administered mutant CRP at the en face
atherosclerotic lesions in mutant CRP-treated mice. As shown
(Figure 5), the lesions in the aorta of mutant CRP-treated mice
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were stained while the lesions in the aorta of untreated mice
did not stain for CRP. The polyclonal anti-human CRP antibody
used in this study does not react with purified murine CRP (data
not shown), consistent with the previously published report that
anti-human CRP antibodies do not react with murine CRP (30).

concentration of lipoproteins in the circulation. As shown in
Table 1, the concentrations of LDL and HDL in the plasma of
untreated and mutant CRP-treated mice were comparable. There
was no statistically significant difference in the levels of either
LDL or HDL in the plasma at any time point between untreated
and mutant CRP-treated groups of mice. Administration of
mutant CRP did not affect the body weight. Body weights of
untreated and mutant CRP-treated mice were similar at each time
point (data not shown).

Mutant CRP Does Not Alter the
Concentration of Lipoproteins in the
Plasma
Injecting a total of 1.6 mg of mutant CRP into mouse, in
32 injections over a period of 9 weeks, did not alter the

DISCUSSION
In this study, we investigated the effects of mutant CRP
F66A/T76Y/E81A, capable of binding to atherogenic LDL
but incapable of binding to PCh, on the development of
atherosclerosis in male ldlr−/− mice. Our major finding was
that the administration of mutant CRP for 7 weeks slowed the
progression of atherosclerosis. The total size of atherosclerotic
lesions in the whole aorta of mice treated with mutant CRP on

TABLE 1 | Concentration of lipoproteins in the plasma.
Week of sacrifice

FIGURE 4 | No reduction in the size of atherosclerotic lesions in the aortic root
of mutant CRP-treated mice. The scatter plot shows the total atherosclerotic
lesion area in aortic root sections from untreated and mutant CRP-treated
mice. Data were collected at five different time points: 1, 3, 5, 7, and 9 weeks
after mutant CRP administration (12 mice per group per time point). Each blue
dot represents one mouse from the untreated group and each green dot
represents one mouse from the mutant CRP-treated group. Horizontal black
lines indicate the median total aortic root lesion area for each group.

HDL (mg/dl)

LDL (mg/dl)

Untreated

CRP-treated

Untreated

CRP-treated

1

61 ± 2

85 ± 19

864 ± 16

713 ± 31

3

91 ± 15

71 ± 19

838 ± 231

786 ± 246

5

78 ± 4

74 ± 12

754 ± 118

7

131 ± 1

107 ± 15

932 ± 86

9

80 ± 3

105 ± 2

1,054 ± 3

834 ± 185
1,086 ± 23
1,103 ± 19

Plasma HDL and LDL levels were analyzed in samples pooled from all 12 mice in each
group. Results are expressed as mean ± SEM.

FIGURE 5 | Immunostaining of mutant CRP in the aorta. (A) A representative aorta from untreated mice stained for mutant CRP. (B) A representative aorta from mice
treated with mutant CRP for 7 weeks, stained for CRP. 1–4 represent an aorta through different stages of staining. (1) Sudan IV-stained aorta. Red colored areas are
the lesions. (2) Aorta post-dehydration to remove Sudan IV. White colored areas are the lesion areas. (3) Anti-human CRP antibody-stained aorta. Brown colored areas
reflect the presence of mutant CRP in the lesions. (4) Magnified aortic arch area of the anti-human CRP antibody-stained aorta. Red boxes show the lesion areas.
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alternate days for 7 weeks and beyond was significantly smaller
(∼40%) than the lesions in the aorta of untreated mice.
Previously, the role of WT CRP in atherosclerosis had been
explored, employing a variety of experimental strategies, and
12 papers have been published using CRP from man, mouse
and rabbit in both murine and rabbit models of atherosclerosis
(31–42). In these studies, both, normal mice and CRP-deficient
mice have been employed. Both, normal rabbits and rabbits in
which CRP was inhibited by using anti-sense technology have
been employed. Both, passively administered CRP and transgenic
human CRP have been employed. Three different types of
atherosclerosis-prone mice, apoE−/− , ldlr−/− , and apoB100/100
ldlr−/− , have been used in these studies. Two of the 12 papers
indicated that both human and murine CRP might be playing
an atheroprotective role: human CRP was shown to slow the
development of atherosclerosis in the apoB100/100 ldlr−/− mice
(36), and the lesion size in CRP-deficient mice on apoE−/− or
ldlr−/− background was either equivalent or increased compared
to that in normal mice (41). In the other 10 papers, regardless
of the experimental strategy used, WT CRP from all species did
not show any effect on the development of atherosclerosis in
animals, suggesting that WT CRP is neither pro-atherogenic nor
anti-atherogenic (25, 43).
The most logical explanation for the observations of zero
or nominal effects of WT CRP (31–42) on atherosclerosis in
animal models is that the animal models of atherosclerosis do
not possess the required inflammatory microenvironment that is
needed by CRP to change its structure and be able to interact with
atherogenic LDL (10, 18, 25). WT CRP shows no effect because
pH near the lesions may not be acidic in animal models and,
therefore, the structure of administered or endogenous WT CRP
remains unchanged (10, 18, 25). WT CRP treated with acidic pH
in vitro was unsuitable for administration into blood circulation
of animals since the acidic pH-induced conformational alteration
in the pentameric structure of CRP was found to be reversible
at physiological pH (17). Therefore, we hypothesized that an in
vitro-generated mutant CRP, capable of binding to atherogenic
LDL without the requirement of any structural modification in
vivo, would be suitable to investigate the mechanism of action
of CRP on the development of the disease in animal models
(10, 16, 18, 25). Indeed, in one study, monomeric CRP, that is
also capable of binding to atherogenic LDL, was employed and
the results showed that monomeric CRP was protective against
atherosclerosis in apoE−/− mice (34). Thus, our current findings
using mutant CRP and previous findings using monomeric CRP,
both molecules capable of binding to atherogenic LDL, indicate
that structurally altered CRP protects against atherosclerosis; it
is just that WT CRP does not exert a protective effect in most
animal models (25, 44).
The effect of mutant CRP on the size of atherosclerotic lesions
in the en face aorta was obvious since we found that administered
mutant CRP had reached the aorta. The staining of aortic
roots for the presence of administered mutant CRP provided
inconclusive results (data not shown). It is assumed that if mutant
CRP reached the aorta, it also reached the aortic root, and if
this assumption is correct, then the effect of mutant CRP was
site-specific. Site-specific effects of experimental manipulations
have been observed in other studies using ldlr−/− mice where the
Frontiers in Immunology | www.frontiersin.org

disease developed differently at various lesion-prone sites (45–
50). Since the effects of mutant CRP were still observed after week
9 in the en face aorta, it is unlikely that anti-CRP antibodies were
produced in response to intravenous administration of mutant
CRP that could have inhibited its functions.
The topology of the LDL-binding site and the number of
LDL-binding sites on mutant CRP remain undefined. Two
possible mechanisms have been proposed for the interaction
between conformationally altered CRP and atherogenic LDL.
The intrinsically disordered region present in CRP has been
shown to participate in the binding of monomeric CRP and
atherogenic LDL (51). We proposed that the loosening of
the CRP pentamer contributed to the formation of the LDLbinding site (16–18, 25). Recently, it has been suggested that the
pentameric assembly of CRP harbors a pronounced plasticity
in inter-subunit interactions, which may form the basis for a
reversible activation of CRP in inflammation (52). However,
it is unknown whether the intrinsically disordered region was
exposed or the pentamer was loosened in mutant CRP employed
in this study. We speculate that there is only one LDL-binding site
per CRP pentamer. However, for the protection of mice against
atherosclerosis, it is possible that both sites, the PCh-binding
site and the LDL-binding site, participate. The search for a new
mutant CRP which can bind to both PCh and to atherogenic
LDL is in progress. Any possible similarity between mutant CRP
used in this study and previously reported conformationally
altered pentameric forms of CRP, pCRP∗ , and mCRPm (20, 21),
is unknown.
Based on the data obtained from a single regimen for
mutant CRP treatment, we conclude that one of the functions
of CRP is to confer protection against atherosclerosis. We
propose, again, that there is no need to stop the biosynthesis
of CRP, and that a drug that can lower cholesterol level but
not CRP levels could be superior to statins which reduce
both CRP and cholesterol levels (53, 54). These suggestions
are supported by the fact that, in rabbits, the inhibition of
plasma CRP did not affect the development of atherosclerosis
(42). It has also been previously postulated that the deposition
of CRP at the atherosclerotic lesions may be independent
of the CRP levels in the circulation and that CRP-mediated
lipoprotein removal likely underlies the regression of early
lesions which occurs continuously throughout life and that CRP
should be considered as an anti-atherosclerotic protein (10,
13). A long-term goal should be the discovery and design of
small-molecule compounds to aid endogenous native CRP in
capturing atherogenic LDL, as proposed earlier (14, 25). Another
goal could be to investigate the possible protective effects of
mutant CRP used in this study in animal models of other
inflammatory diseases.
Our data also provide a proof of concept that
a local inflammation-induced structural change in
native CRP is a prerequisite for CRP to control the
development of atherosclerosis. An appropriate inflammatory
microenvironment at the site of LDL deposition seems to be
critical for CRP to prevent atherosclerosis. One function of
inflammation could be to change the structure of proteins,
including CRP. Inflammation is not a silent killer, perhaps, as
has been suggested (55).
6
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